General Information of the Protein
| Protein ID |
PT00016
|
||||
|---|---|---|---|---|---|
| Protein Name |
Enoyl-acyl-carrier protein reductase
|
||||
| Gene Name |
FABI
|
||||
| Sequence |
MNKISQRLLFLFLHFYTTVCFIQNNTQKTFHNVLQNEQIRGKEKAFYRKEKRENIFIGNKMKHVHNMNNTHNNNHYMEKEEQDASNINKIKEENKNEDICFIAGIGDTNGYGWGIAKELSKRNVKIIFGIWPPVYNIFMKNYKNGKFDNDMIIDKDKKMNILDMLPFDASFDTANDIDEETKNNKRYNMLQNYPIEDVANLIHQKYGKINMLVHSLANAKEVQKDLLNTSRKGYLDALSKSSYSLISLCKYFVNIMKPQSSIISLTYHASQKVVPGYGGGMSSAKAALESDTRVLAYHLGRNYNIRINTISAGPLKSRAATAINKLNNTYENNTNQNKNRNSHDVHNIMNNSGEKEEKKNSASQNYTFIDYAIEYSEKYAPLRQKLLSTDIGSVASFLLSRESRAITGQTIYVDNGLNIMFLPDDIYRNENE
Show/Hide
|
||||
| Organism |
Plasmodium falciparum, malaria parasite P. falciparum
|
||||
| Protein Classification |
Enzyme
|
||||
| Uniprot ID | |||||
Clinical Information about the Protein
Target 1 ( Plasmodium Enoyl-ACP reductase (Malaria fabI) )
| Target Type | Successful Target | ||||
|---|---|---|---|---|---|
| Disease | 2 Target-related Diseases | 2 | |||
| 1 | Hepatic fibrosis [ICD-11: DB93.0] | ||||
| 2 | Malaria [ICD-11: 1F40-1F45] | ||||
| Approved Drug(s) | 1 Approved Drug | 1 | |||
| 1 | Triclosan | Approved | |||
| Clinical Trial Drug(s) | 1 Clinical Trial Drug | 1 | |||
| 1 | Epigallocatechin gallate | Phase 3 | |||
| Investigative Drug(s) | 1 Investigative Drug | 1 | |||
| 1 | Thiolactomycin | Investigative | |||